Navigation Links
Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
Date:2/3/2009

ted the study. Study patients in the treatment group received a total of 400 mg/day of 6R-BH4 twice per day. Approximately 50% of patients in both the placebo and treatment groups were co-administered Vitamin C at 500 mg/day twice daily.

The primary objective of the study was to evaluate mean change in peak walking time from baseline to week 24. The secondary objective of the study was to evaluate the mean change in claudication onset time from baseline to week 24.

About 6R-BH4

6R-BH4, commonly known as BH4 or tetrahydrobiopterin, is a naturally occurring enzyme cofactor that is required for numerous biochemical and physiologic processes, including the synthesis of nitric oxide (NO). NO has been shown to play a key protective role throughout the cardiovascular system and produces multiple positive effects, such as relaxing smooth muscle, reducing blood pressure, controlling inflammation and reducing platelet aggregation. Researchers have demonstrated that a deficiency of BH4 can disrupt NO synthesis, resulting in a loss of normal endothelial NO production. This loss of endothelial NO production, commonly referred to as endothelial dysfunction, has been associated with many cardiovascular diseases, including hypertension, diabetic vascular disease, peripheral arterial disease, coronary arterial disease and pulmonary hypertension, and has been shown to be a strong predictor of cardiovascular adverse events in a number of clinical studies.

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
2. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
3. Corgenix to Host Conference Call to Discuss Second Quarter Results
4. BioMed Realty Trust to Report 2008 Fourth Quarter and Year-End Results
5. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
6. Cardica Announces Fiscal 2009 Second Quarter Financial Results
7. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
8. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
9. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
10. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
11. Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... ... Biophotonics industry.The report provides a basic overview of the industry including definitions, classifications, ... international markets including development trends, competitive landscape analysis, and key regions development status. ...
(Date:7/27/2015)... , July 27, 2015   Inocucor ... produces sustainable biological accelerators for farmers, has received ... and Trademark Office for its patent application to ... accelerate plant growth and enhance yields on farms ... relates to Inocucor,s live IN-M1 microbial consortium and ...
(Date:7/27/2015)... -- According to the new Market Research Report ... by Application (Biobanking, Regenerative Medicine, Drug Discovery), by Geography ( ... Asia-Pacific , Rest of the World) - ... was valued at $247.7 million in 2014, which is estimated ... CAGR of 18.2% between 2014 and 2019. Browse ...
(Date:7/27/2015)... Maine , July 27, 2015 IDEXX ... more than 8,000 clinics have submitted over 100,000 specimens ... testing in just the first 10 days since the ... kidney disease (CKD) is a leading cause of suffering ... the submitted specimens are consistent with generally accepted kidney ...
Breaking Biology Technology:2015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5
... THE WOODLANDS, Texas, June 17 ... an Orphan Product Development Grant by the FDA,to support ... Pediatric Ventricular Assist Device (VAD). Dr. Christopher Almond of,the ... of,Clinical Affairs for Berlin Heart Inc. will serve as ...
... for liquid culture tests will accelerate access to improved ... BD (Becton, Dickinson and Company; NYSE: BDX ... (Foundation for Innovative New Diagnostics), a Swiss foundation that ... tools for poverty-related diseases, today announced a significant price ...
... OSLO, Norway, June 17 , ... to Improve Remission Rates and,Reduce Short-Term Mortality Compared to ... ASA (OSE: CLAVIS) today announces positive final results,from a ... elacytarabine,(CP-4055), in patients with late-stage acute myeloid leukaemia (AML). ...
Cached Biology Technology:Berlin Heart Inc. Receives FDA Orphan Product Development Grant 2BD and FIND Achieve Milestone in Global Battle Against MDR-TB 2BD and FIND Achieve Milestone in Global Battle Against MDR-TB 3BD and FIND Achieve Milestone in Global Battle Against MDR-TB 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7
(Date:7/23/2015)... , July 23, 2015 Research and ... of the "Global Outlook of the Biometrics ... The global biometrics market is ... and commercial applications owing to the uptake of ... a transformation that enhances the growth of biometrics ...
(Date:7/20/2015)... July 20, 2015  Acuity Market Intelligence,s latest ... Convergence of Commerce and Privacy" forecasts that between ... apps will be downloaded to smart mobile devices ... biometrics market is projected to generate more than ... the seven-year forecast period.    "Biometrics ...
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... studies could lead to a radical re-thinking about how ... "Six of the adult females that we followed ... far out on the Arctic sea ice," said Universit ... Professor Gilles Gauthier as part of an International Polar ...
... Michigan State University chemist could eventually lead to a ... are key to treating a number of diseases, including ... manufacture and research often are made within genetically modified ... tends to collect into what scientists call inclusion bodies. ...
... the Faculty of Life Sciences (LIFE) at the University of ... than milk chocolate, lessening our craving for sweet, salty and ... an efficient way to keep your weight down over Christmas. ... it is healthier to eat dark chocolate, but now scientists ...
Cached Biology News:Snowy owl -- a marine species? 2The dark chocolate version of Father Christmas is most filling 2
... • Enzyme concentration - 5 units/µL ... in higher yields ,• Leaves an 'A' ... DNA polymerase which exhibits very high activity ... applications. To ensure the quality of the ...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
... DNA Polymerase is the most thoroughly characterized ... testimony to its overall utility and efficacy. ... ideal for PCR applications. , It ... ,, AmpliTaq DNA Polymerase is a ...
... DNA Polymerase is a versatile and easy-to ... PCR applications. GCpro Taq DNA Polymerase is ... E. coli, containing the DNA polymerase I ... a highly processive 5'-3' DNA polymerase activity. ...
Biology Products: